IPSC · Century Therapeutics, Inc. · Documents

Aug 8

Current report 8-K

Financial results, Regulation FD disclosure

Aug 8

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $771K ▲ 678.8% Net loss $31.21M Diluted EPS -$0.38

Jul 8

Current report 8-K

Other events

Jun 26

Current report 8-K/A Events of Apr 11

Current report

Jun 24

Current report 8-K Events of Jun 20

Shareholder vote results

Jun 18

Registration statement S-3

Registration statement

Jun 3

Current report 8-K

Other events

May 15

Registration statement S-3

Registration statement

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $855K ▼ 50.3% Net loss $28.06M

Apr 26

Proxy statement DEF 14A Meeting Jun 20, 2024

Proxy statement

Apr 26

Annual report to holders ARS

Annual report to holders

Apr 26

Proxy statement DEFA14A

Proxy statement

Apr 16

Proxy statement PRE 14A Meeting Jun 20, 2024

Proxy statement

Apr 11

Current report 8-K

Other events

Apr 11

Current report 8-K

Completed an acquisition or sale of assets, Unregistered sale of equity, Regulation FD disclosure

Apr 9

Current report 8-K Events of Apr 8

Other events

Mar 14

Current report 8-K

Financial results, Regulation FD disclosure

Mar 14

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $2.24M ▼ 57.0% Net loss $136.67M Diluted EPS -$2.27

Jan 19

Current report 8-K Events of Jan 15

Director or officer change, or executive pay

Dec 11

Current report 8-K Events of Dec 9

Other events

Dec 6

Current report 8-K

Other events

Nov 14

Current report 8-K Events of Nov 7

Director or officer change, or executive pay

Nov 9

Current report 8-K

Financial results, Regulation FD disclosure

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $148K ▼ 93.3% Net loss $32.72M Diluted EPS -$0.55

Oct 3

Current report 8-K

Other events

Aug 9

Current report 8-K

Financial results, Regulation FD disclosure

Aug 9

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $99K ▼ 92.9% Net loss $33.29M Diluted EPS -$0.56

Jun 29

Current report 8-K Events of Jun 27

Shareholder vote results

May 11

Current report 8-K

Financial results

May 11

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $1.72M ▲ 62.6% Net loss $31.26M Diluted EPS -$0.53

May 5

Current report 8-K/A Events of Apr 11

Director or officer change, or executive pay

May 5

Current report 8-K Events of May 1

Ended a material agreement

Apr 28

Proxy statement DEF 14A Meeting Jun 27, 2023

Proxy statement

Apr 28

Annual report to holders ARS

Annual report to holders

Apr 28

Proxy statement DEFA14A

Proxy statement

Apr 17

Current report 8-K Events of Apr 11

Director or officer change, or executive pay

Mar 20

Current report 8-K

Regulation FD disclosure

Mar 16

Current report 8-K

Financial results

Mar 16

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $5.2M Net loss $130.93M Diluted EPS -$2.27

Mar 13

Current report 8-K

Regulation FD disclosure

Jan 9

Current report 8-K Events of Jan 5

Regulation FD disclosure, Other events

Nov 30

Current report 8-K

Regulation FD disclosure

Nov 10

Current report 8-K

Financial results

Nov 10

Current report 8-K

Regulation FD disclosure

Nov 10

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $2.22M Net loss $30.75M Diluted EPS -$0.53

Oct 3

Current report 8-K Events of Sep 28

Director or officer change, or executive pay

Sep 8

Current report 8-K

Regulation FD disclosure

Aug 25

Current report 8-K

Other events

Aug 11

Current report 8-K

Financial results